Genetic counselors are trying once again to gain Medicare recognition through this bill, so they can bill for their services.
Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...
Tecentriq, Avastin Regimen Beats Anti-PD-L1 Monotherapy in MMR-Deficient, MSI-High Colorectal Cancer
Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...
CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...
The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.
So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.
The firm is looking ahead to Phase III Kimmtrak results in cutaneous melanoma and early-stage readouts from its PRAME candidates.
Jazz Pharma to Submit Ziihera Data in First-Line HER2-Positive Gastroesophageal Cancer to Regulators
In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.
The startup aims to create a platform for treating extremely rare genetic mutations, armed with CRISPR advances and new regulatory pathways.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback